Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
56 participants
OBSERVATIONAL
2014-02-28
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Natural History of Small Renal Masses
NCT01305330
Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary
NCT05841966
Evaluation of Preoperative Investigations in Patients With Liver Cancer
NCT00408122
Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma
NCT04424472
Porto-Venous Radiomics in Pancreatic Cancer
NCT05700110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Benign primary renal masses include simple renal cysts, psuedotumours, angiomyolipomas, oncocytomas, juxtaglomerular tumours, multilocular cystic nephromas, mesoblastic nephromas and papillary adenomas. In a recent surgical series of 228 patients who underwent partial or radical nephrectomy with lesions ≤4 cm, 26.3% were benign \[3\]. The relatively high percentage of patients with benign renal cortical neoplasms who undergo surgery highlights the importance of new diagnostic technology in avoiding over-treatment.
Ultrasound (US) and CT scanning guided biopsy is the most commonly used method to diagnosis RCC. The sensitivity of biopsy for small masses (≤3 cm) is lower than for large masses \[4\]. Sensitivity is limited by false-negative results, which are due to a failure to properly target a small mass or the presence of impossible-to-differentiate benign from malignant cells due to insufficient cells, morphological overlap or cellular heterogeneity. Non diagnostic biopsy is not necessary benign, as repeated biopsy reveals malignancy diagnosis in the majority\[5\]. There is no radiologic criteria consistent with oncocytoma because of a lack of sensitivity and specificity \[6\]. MR-scanning and CT-scanning are not feasible diagnostic methodologies for oncocytoma because of the possibility of overlapping results from oncocytoma and RCC \[7\].
Hypotheses: To investigate the ability of perfusion CT/US-scanning to facilitate recognition of different tumour sub-types in small renal masses less than 7 cm by non-invasive imagining technology.
Purpose: To recognize different subtype's renal tumor by non invasive scanning. Design: A descriptive study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oben label
There is no intervention on this descriptive study
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients age between 35 and 75 years
3. Normal renal function
4. Can read and understand Danish
5. Non - metastasis disease detected by scanning
Exclusion Criteria
2. Previous allergic reaction to intravenous contrast material.
3. Untreated hyperthyroidism.
4. Pregnancy.
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nessn Azawi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nessn Azawi
consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nessn Azawi, M.D.
Role: PRINCIPAL_INVESTIGATOR
Zealand University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Roskilde Hospital
Roskilde, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SJ-366
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
SJ-366
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.